Skip to main content
Synbiotic SE logo

Synbiotic SE — Investor Relations & Filings

Ticker · SBX ISIN · DE000A3E5A59 LEI · 48510041U2G1IWA3R418 F Manufacturing
Open in API
Filings indexed 140 across all filing types
Latest filing 2022-09-21 Share Issue/Capital Cha…
Country DE Germany
Listing F SBX

About Synbiotic SE

https://www.synbiotic.com/

Synbiotic SE is a European corporate group focused on the medical cannabis and industrial hemp markets. The company operates a platform model, making strategic investments in ventures across these sectors to create synergies. Its business is vertically integrated, covering the entire value chain from cultivation, research, and development to the production, sales, and distribution of hemp- and cannabinoid-based products. The company's portfolio includes a wide range of high-quality hemp, CBD, and cannabis products, leveraging its expertise across the full supply chain from seed to shelf.

Recent filings

Filing Released Lang Actions
SynBiotic SE: Anderung des Platzierungspreises aus der am 2. September 2022 beschlossenen Barkapitalerhohung
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad-hoc' announcement dated September 21, 2022, classified as 'Insiderinformation gem. Artikel 17 MAR'. The core content announces a change in the placement price for a previously decided cash capital increase ('Barkapitalerhöhung'). This action directly relates to the company's financing activities and capital structure adjustments. This fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific financing event.
2022-09-21 German
SynBiotic SE: Durchfuhrung einer Kapitalerhohung beschlossen
Share Issue/Capital Change Classification · 98% confidence The document is an 'Ad-hoc' announcement dated September 2, 2022, explicitly titled "SynBiotic SE: Durchführung einer Kapitalerhöhung beschlossen" (SynBiotic SE: Resolution to carry out a capital increase). It details the decision by the Administrative Board to increase the share capital by issuing new shares against cash contributions, excluding pre-emptive rights, and mentions the placement price and intent to offer shares to institutional investors. This action directly relates to fundraising, financing activities, and changes in the capital structure. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific corporate finance event.
2022-09-02 German
Hempamed Rx: SynBiotic SE launches full-line medical cannabis brand
Regulatory Filings Classification · 100% confidence The document is a press release titled "Hempamed Rx: SynBiotic SE launches full-line medical cannabis brand" and is disseminated via DGAP-News. It announces a product launch, restructuring of sales/distribution entities, and upcoming participation in a trade fair (Expopharm). This type of announcement, focusing on a new product line and business strategy update rather than periodic financial results (ER/IR) or formal regulatory filings (10-K/AR), fits best under a general regulatory announcement or news release category. Since it is a specific business update disseminated through a news service (DGAP), and it doesn't fit the specific definitions for ER, IR, CAP, or MANG, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements. It is not an Earnings Release (ER) as it focuses on product launch, not financial figures. It is not an Investor Presentation (IP) as it is a news release format. It is not a Report Publication Announcement (RPA) because it is announcing an action (product launch/sales expansion), not announcing the publication of a separate, attached report.
2022-09-01 English
Hempamed Rx: SynBiotic SE launcht eigene Vollsortimenter Medical Cannabis Brand
Regulatory Filings Classification · 100% confidence The document is explicitly labeled as a "Press Release" and contains a DGAP-Media header, indicating it is a public announcement disseminated via a news service (EQS Group AG). The content announces the launch of a new brand ('Hempamed Rx') and associated business restructuring (sales team expansion, subsidiary renaming) related to medical cannabis. This type of announcement, which communicates a specific business event or product launch outside of routine financial reporting (like 10-K or ER), typically falls under general regulatory announcements or news releases. Since it is not a formal financial report (10-K, IR, ER) nor a specific corporate action like a dividend (DIV) or insider trade (DIRS), and it is a news release format, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements not covered by more specific codes. The document length is moderate (under 5,000 characters), but its primary function is to disseminate news, not to be the report itself.
2022-08-30 German
Becoming a cannabis ecosystem: SynBiotic SE management update
Regulatory Filings Classification · 100% confidence The document is a news release dated August 3, 2022, disseminated via DGAP (a service of EQS Group AG), which typically handles regulatory announcements and corporate news. The content provides a management update, highlights new product launches (CBPlus, Hempamed Rx), reports preliminary pro-forma sales (€15 million for 2021), and announces the timing of the next annual shareholders' meeting (Q4 2022). It is not a full Annual Report (10-K), an Interim Report (IR), or a formal Earnings Release (ER) which usually contains detailed financial tables. It is an announcement about company activities, strategy, and upcoming events, including a mention of the AGM. Since it is a general corporate news update disseminated through a regulatory news service (DGAP) and covers various operational and strategic points, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a broad corporate announcement that doesn't strictly match the more specific categories like ER, MDA, or AGM-R (which is for the meeting materials themselves, not the announcement of the meeting date). Given the context of DGAP dissemination and the nature of the update, RNS is the most appropriate fallback for a general corporate news item.
2022-08-03 English
SynBiotic SE - Individual Financial Statement 2021 HGB (DE | PDF)
Annual Report Classification · 95% confidence The document is a formal 'Jahresabschluss' (Annual Financial Statement) for SynBiotic SE for the fiscal year ending December 31, 2021. It includes the auditor's report ('Bestätigungsvermerk') from Mazars GmbH & Co. KG, the balance sheet ('Bilanz'), and references to the profit and loss statement ('Gewinn- und Verlustrechnung'). While it contains audit information, it is the primary annual financial reporting document for the company, which falls under the 'Annual Report' (10-K) category in this taxonomy, as it represents the comprehensive yearly financial performance report. FY 2021
2022-04-25 German

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.